Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

ABSTRACT: Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

PROVIDER: PRJNA611620 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

Project description:Eribulin, irinotecan, and the combination were studied in ES4 xenograft model. RNAs from xenograft tumors were harvested at 24h and 144h after single agent or combination treatment to analyze gene expression.

2020-03-10 | GSE146687 | GEO

Gene expression in pediatric acute lymphoblastic leukemia patient-derived xenografts

2015-10-24 | GSE74299 | GEO

Gene expression in pediatric acute lymphoblastic leukemia patient-derived xenografts

Project description:In this study, pediatric ALL patient-derived xenografts (PDXs) inherently resistant to glucocorticoids were cultured in vitro. The study aims to determine discrepancy in gene expressions between different xeno strains. The same xenograft was innoculated into 3 mice. Spleen-harvest xenograft samples were analyzed using microarray.

2015-10-24 | E-GEOD-74299 | biostudies-arrayexpress

Patient-derived xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management

Project description:Identification of new treatments for relapsing pediatric cancer is an unmet clinical need and a societal challenge. Liver cancer occurrence in infancy, 1.5 for million children per year, falls far below the threshold of interest for the development of dedicated drug development programs, and this disease is too rare and heterogeneous to gather enough children into a clinical trial. Here, we present the establishment of an unprecedented preclinical platform of 24 pediatric liver cancer patient-derived xenografts (PLC-PDXs) from 20 hepatoblastomas, 1 transitional liver cancer tumor, 1 hepatocellular carcinoma and two rhabdoid tumors. SNP array and mutational analysis of the parental tumors and the corresponding PLC-PDXs show high conservation of the molecular features of the parental tumors. The histology of PLC-PDXs is strikingly similar to that observed in primary tumors, and recapitulates well the heterogeneity of recurrent disease observed in the clinic. Tumor growth in the mouse is strongly associated with elevated circulating alpha-fetoprotein (AFP), low rate of necrosis/fibrosis after treatment and gain of chromosome 20, all indicators of resistance to chemotherapy and poor outcome. Accordingly, the ability of a tumor to generate PLC-PDX is predictive of poor prognosis. Exposure of PLC-PDXs to standards of care or therapeutic options already in use for other pediatric malignancies revealed unique response profiles in these models. Among these combinations, irinotecan/temozolomide induced strong tumor regression in the transitional liver cancer tumor model and on a model derived from AFP-negative relapsing HB. These results provide promising evidence that this preclinical platform can strongly contribute to accelerate the identification and diversification of anti-cancer treatment for aggressive subtypes of pediatric liver cancer.

2016-06-03 | GSE76100 | GEO

scRNA-seq of pediatric glioblastoma patient-derived xenografts

Project description:scRNA-seq of pediatric glioblastoma patient-derived xenografts

| PRJNA482625 | ENA

Phosphoproteome analysis of pediatric acute leukemia patients and matched xenografts

Project description:Proteomics reveal PTM stability after xenotransplantation in murine models. Phosphopeptides enriched using magnetic FeNTA beads were analyzed by Data Independent Acquisition (DIA) mass spectrometry. High-pH fractionation was performed on a pool of samples, followed by data dependent acquisition (DDA) mass spectrometry analysis. Spectral information from DDA and DIA data were used to generate a sample-specific library for targeted analysis to identify and quantify proteins. We present phosphorylation profiles for paired patients and patient-derived xenografts, pediatric leukemic cell lines, and normal individuals.

2019-12-02 | MSV000084645 | MassIVE

Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.

Project description: Not available

| S-EPMC7299830 | biostudies-literature

N terminome analysis of pediatric acute leukemia patients and matched xenografts

Project description:Proteomics reveal PTM stability after xenotransplantation in murine models. N termini enriched using HUNTER technique were analyzed by Data Independent Acquisition (DIA) mass spectrometry. High-pH fractionation was performed on a pool of samples, followed by data dependent acquisition (DDA) mass spectrometry analysis. Spectral information from DDA and DIA data were used to generate a sample-specific library for targeted analysis to identify and quantify proteins. We present a global landscape of proteolytic processing in paired patients and patient-derived xenografts, pediatric leukemic cell lines, and normal individuals.

2019-12-02 | MSV000084643 | MassIVE

Global protein analysis of pediatric acute leukemia patients and matched xenografts

Project description:Proteomics reveal protein stability after xenotransplantation in murine models. Tryptic peptide digests from patient mononuclear cells were analyzed by Data Independent Acquisition (DIA) mass spectrometry. High-pH fractionation was performed on a pool of samples, followed by data dependent acquisition (DDA) mass spectrometry analysis. Spectral information from DDA and DIA data were used to generate a sample-specific library for targeted analysis to identify and quantify proteins. We present a global landscape of protein stability in paired patients and patient-derived xenografts, pediatric leukemic cell lines, and normal individuals.

2019-12-02 | MSV000084646 | MassIVE

Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft [II]

Project description:Desmoplastic small round cell tumor (DSRCT) is a rare and incurable malignancy characterized by the oncogenic EWSR1-WT1 transcription factor. This study exploited a novel DSRCT patient-derived xenograft (PDX), which reproduces histomorphological and molecular characteristics of the paired clinical tumor, to comparatively assess the activity of cytotoxic and targeted anticancer agents. Anti-tumor effect was moderate for single-agent doxorubicin, pazopanib and larotrectenib [maximum tumor volume inhibition (max TVI): 55-66%] while trabectedin had a higher effect (max TVI: 82%). Single-agent vinorelbine, irinotecan and eribulin achieved a nearly complete tumor growth inhibition (max TVI: 96-98%), although tumors started to re-growth after the end of treatment. Combination of irinotecan with either eribulin or trabectedin resulted in complete responses which were maintained until the end of the experiment for irinotecan plus trabectedin. Irinotecan-based combinations almost completely abrogated the expression of proteins involved in the G2/M checkpoint preventing cell entrance in mitosis and induced apoptotic and necroptotic cell death. This study emphasizes the importance of patient-derived pre-clinical models to explore new treatments in DSRCT and fosters clinical investigation in the activity of irinotecan plus trabectedin.

2023-05-29 | GSE227897 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data